Monitoring the effects of BCNU chemotherapy Wafers (Gliadel®) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla

Journal of Neuro-Oncology

Volumn 82, Issue 1, 2007, Pages 103-110

  Dyke, Jonathan P ^a   Sanelli, Pina C ^a   Voss, Henning U ^a   Serventi, Jennifer V ^a   Stieg, Philip E ^a   Schwartz, Theodore H ^a   Ballon, Douglas ^a   Shungu, Dikoma C ^a   Pannullo, Susan C ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cancer; Chemotherapy; Gliadel; Glioblastoma; Glioma; MRI; MRSI; Spectroscopy

Indexed keywords

CARMUSTINE; CHOLINE; CREATINE; LACTIC ACID; N ACETYLASPARTIC ACID; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRAIN SURGERY; BRAIN TISSUE; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CASE REPORT; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GLIOBLASTOMA; HUMAN; LOW DRUG DOSE; MEDICAL ASSESSMENT; MULTIPLE CYCLE TREATMENT; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOSURGERY; TISSUE METABOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR REGRESSION;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; DECANOIC ACIDS; DRUG CARRIERS; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PILOT PROJECTS; POLYESTERS; TREATMENT OUTCOME;

EID: 33846981209     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-006-9254-6     Document Type: Article

References (25)

1. American Cancer Society Cancer Facts & Figures 2005 (2005) American Cancer Society, Atlanta
2. Bleehen NM, Stenning SP (1991) A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 64:769-774
3. Reddy LH (2005) Drug delivery to tumours: Recent strategies. J Pharm Pharmacol 57:1231-1242
4. Fleming AB, Saltzman WM (2002) Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 41:403
5. Gliadel [prescribing information] (2003) Guilford Pharmaceuticals Inc., Baltimore, MD
6. Prager JM, Grenier Y, Cozzens JW, Chiowanich P, Gorey MT, Meyer JR (2000) Serial CT and MR imaging of carmustine wafers. AJNR Am J Neuroradiol 21:119-123
7. Leeds N, Kumar A, Jackson E (2002) Diagnostic imaging. In: Levin V (ed) Cancer in the nervous system. Oxford University Press, New York, pp 3-59
8. Li X, Jin H, Lu Y, Oh J, Chang S, Nelson SJ (2004) Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 17:10-20
9. Duyn JH, Gillen J, Sobering G, van Zijl PC, Moonen CT (1993) Multisection proton MR spectroscopic imaging of the brain. Radiology 188:277-282
10. Gajewicz W, Papierz W, Szymczak W, Goraj B (2003) The use of proton MRS in the differential diagnosis of brain tumors and tumor-like processes. Med Sci Monit 9:MT97-MT105
11. Preul MC, Caramanos Z, Villemure JG, Shenouda G, LeBlanc R, Langleben A, Arnold DL (2000) Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 46:306-318
12. Oh J, Henry RG, Pirzkall A, Lu Y, Li X, Catalaa I, Chang S, Dillon WP, Nelson SJ (2004) Survival analysis in patients with glioblastoma multiforme: Predictive value of choline-to- N -acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imag 19:546-554
13. 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy. J Neurooncol 76:185-191
14. Aboagye EO, Bhujwalla ZM (1999) Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 59:80-84
15. Schlemmer HP, Bachert P, Henze M, Buslei R, Herfarth KK, Debus J, van Kaick G (2002) Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology 44:216-222
16. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, Berger MS, Chang S (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: Data from the Glioma Outcomes Project. J Neurosurg 99:467-473
17. Fung LK, Ewend MG, Sills A, Sipos EP, Thompson R, Watts M, Colvin OM, Brem H, Saltzman WM (1998) Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 58:672-684
18. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008-1012
19. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T (1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 41:44-48 discussion 48-49
20. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 5:79-88
21. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E (2006) On behalf of the Executive Committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148:269-275
22. Rees J (2003) Advances in magnetic resonance imaging of brain tumours. Curr Opin Neurol 16:643-650
23. Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA (2002) How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 59:947-949
24. Matheus MG, Castillo M, Ewend M, Smith JK, Knock L, Cush S, Morris DE (2004) CT and MR imaging after placement of the GliaSite radiation therapy system to treat brain tumor: Initial experience. AJNR Am J Neuroradiol 25:1211-1217
25. Grossman SA, Reinhard C, Colvin OM, Chasin M, Brundrett R, Tamargo RJ, Brem H (1992) The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 76:640-647